Sempre Health rakes in $8 million to improve patient behavior and medication adherence
Rethink Impact led the Series A round, which will be used to grow Sempre's relationships with health plans and to make its service available to more patients.
Rethink Impact led the Series A round, which will be used to grow Sempre's relationships with health plans and to make its service available to more patients.
The medication adherence collaboration with Novo Nordisk and Sempre Health will focus on incentivizing diabetes patients.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Sempre Health Cofounder and CEO Anurati Mathur said the first pilot will focus on heart patients.